Get the latest news, insights, and market updates on HROW (Harrow, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Harrow Announces Closing of Acquisition of Melt Pharmaceuticals
NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the acquisition of Melt Pharmaceuticals, Inc. (Melt), a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and in-office settings. Melt’s product candidates, MELT-210, MELT-300, and MELT-400, are based on the propri Nov 18, 2025 - $HROW
Harrow (HROW) Is Up After Q3 Profit Turnaround and Revenue Growth Are Reported – What's Changed
Harrow, Inc. recently reported third-quarter 2025 results, highlighting a revenue increase to US$71.64 million and a move from a net loss to a net profit compared to the same period last year. The company’s swing to profitability, following a period of losses, signals a significant operational improvement within its core business. We'll examine how Harrow's return to profit and strong revenue performance could influence its outlook for future growth. We've found 16 US stocks that are... Nov 11, 2025 - $HROW
Assessing Harrow (HROW) Valuation Following Strong Q3 Growth and New Product Momentum
Harrow (HROW) just released its third-quarter earnings, reporting impressive revenue and a return to profitability compared to last year. The update highlights the company's momentum and ongoing strategic efforts. See our latest analysis for Harrow. Despite a robust Q3 earnings headline, Harrow’s share price has softened recently, with a 7-day share price return of -5.1% and a 30-day return of -8.9%. Still, when you zoom out, the stock’s three- and five-year total shareholder returns of 194%... Nov 11, 2025 - $HROW
Harrow: Q3 Earnings Snapshot
NASHVILLE, Tenn. AP) — Harrow, Inc. HROW) on Monday reported net income of $1 million in its third quarter. Nov 10, 2025 - $HROW
Harrow Announces Third Quarter 2025 Financial Results
Third-Quarter 2025 and Recent Selected Highlights: Total revenues of $71.6 million, a 45% increase over $49.3 million recorded in the prior-year periodGAAP net income of $1.0 millionAdjusted EBITDA of $22.7 millionCash and cash equivalents of $74.3 million as of September 30, 2025 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solut Nov 10, 2025 - $HROW
Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 11, 2025NASHVILLE, Tenn., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the third quarter ended September 30, 2025, on Monday, November 10, 2025, after the market close. The Company will also post its third quarter Letter to Stockholders to the “Investors” s Oct 27, 2025 - $HROW
Harrow, Inc. (HROW): A Bull Case Theory
We came across a bullish thesis on Harrow, Inc. on Make Money, Make Time’s Substack by Oliver | MMMT Wealth. In this article, we will summarize the bulls’ thesis on HROW. Harrow, Inc.’s share was trading at $47.88 as of September 24th. HROW’s trailing and forward P/E were 9.64 and 51.55 respectively according to Yahoo Finance. Harrow […] Oct 8, 2025 - $HROW
Could Harrow’s (HROW) New Pricing Program Redefine Its Patient Access Advantage?
In late September 2025, Harrow, Inc. launched the Harrow Access for All (HAFA) program, expanding affordable and predictable pricing for its full portfolio of branded, generic, and compounded ophthalmic medications, with out-of-pocket costs capped and a streamlined prescribing portal for physicians and patients. This initiative, which builds on earlier access programs, aims to set a new standard for medication affordability while positioning Harrow as a leader in patient-centric access in... Oct 7, 2025 - $HROW
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple